Snca A53T Alpha Synuclein Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Description: Neurons carrying the SNCA-A53T (alpha-synuclein A53T) mutation, a highly pathogenic variant causing familial Parkinson's disease and related synucleinopathies.
The A53T mutation (c.209G>A, p.Ala53Thr) in the SNCA gene was the first discovered genetic cause of autosomal dominant Parkinson's disease. This mutation was identified in the Contursi kindred, an Italian family with multiple affected individuals spanning generations.
The A53T mutation:
- Accelerates alpha-synuclein fibrillization by 10-1000-fold
- Promotes formation of toxic oligomers
- Enhances membrane binding
- Increases neuronal susceptibility to aggregation
Neurons with A53T show:
- Rapid formation of Lewy body-like inclusions
- Impaired autophagy-lysosomal pathway
- Mitochondrial dysfunction
- Endoplasmic reticulum stress
- Synaptic dysfunction
- iPSC-derived neurons: Patient-derived lines with SNCA-A53T
- Gene-edited neurons: Isogenic SNCA-A53T and A53T+/+ lines
- Transgenic models: AAV-mediated SNCA-A53T expression
- A53T neurons exhibit early-onset alpha-synuclein pathology
- Mitochondrial complex I dysfunction is prominent
- Calcium dysregulation precedes inclusion formation
- Selective vulnerability of dopaminergic neurons
- Immunotherapies: Anti-alpha-synuclein antibodies (cinpanemab, prasinezumab)
- Small molecule inhibitors: Compounds preventing aggregation
- Gene silencing: ASO and siRNA approaches
- Anle138b: Oligomer modulator in clinical trials
- ELPCs: Epigallocatechin-3-gallate derivatives
The study of Snca A53T Alpha Synuclein Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- SNCA A53T mutation in familial PD (1997)
- Alpha-synuclein aggregation mechanisms (2019)
- iPSC models of SNCA-A53T (2014)
- Alpha-synuclein immunotherapy trials (2022)